West Nile Virus Nucleic Acid Firms Will Hear Regulatory Guidance Nov. 4-5
This article was originally published in The Gray Sheet
Executive Summary
Blood banks expect to begin screening donated blood for the West Nile Virus using nucleic acid tests (NAT) by mid-2003 under an IND exemption
You may also be interested in...
West Nile Screening Is Only First Step To Broader Virus Protection – Panel
FDA hopes that efforts to develop a blood screening assay for West Nile virus will lead to technology that can be adapted to screen for other rare, endemic flaviviruses
CBER Pledges To Create Standards Boosting WNV Screening Development
FDA's Center for Biologics Evaluation & Research will establish performance criteria and standards to facilitate the development of nucleic acid tests (NAT) to screen donated blood for the West Nile virus
West Nile Screening Is Only First Step To Broader Virus Protection – Panel
FDA hopes that efforts to develop a blood screening assay for West Nile virus will lead to technology that can be adapted to screen for other rare, endemic flaviviruses